| CATALYST PHARMACEUTICAL |
| USA |
| Gesundheit |
| US14888U1016 / A0LCUL |
| CN2 (Frankfurt) / CPRX (NASDAQ) |
| FRA:CN2, ETR:CN2, CN2:GR, NASDAQ:CPRX |
| - |
| https://catalystpharma.co.. |
|
Catalyst Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, particularly in neuromuscular, neuro..
>Volltext.. |
| 2612.51 Mio. EUR |
| 2018.1 Mio. EUR |
| 504.4 Mio. EUR |
| 253.44 Mio. EUR |
| 183.54 Mio. EUR |
| 1.5 EUR |
| 2.39 Mio. EUR |
| 607.32 Mio. EUR |
| 178.7 Mio. EUR |
| 4.82 |
| 5.57% |
| 15.27% |
| - |
| - |
| - |
| - |
| CATALYST PHARMACEUTICAL, CATALYST PHARMACEUTICALS, CATALYST PHARMA |
| 08.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|